Focused On-demand Library for Immunoglobulin-binding protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P78318

UPID:

IGBP1_HUMAN

Alternative names:

B-cell signal transduction molecule alpha 4; CD79a-binding protein 1; Protein phosphatase 2/4/6 regulatory subunit; Renal carcinoma antigen NY-REN-16

Alternative UPACC:

P78318; Q8TAB2

Background:

Immunoglobulin-binding protein 1, also known as B-cell signal transduction molecule alpha 4, CD79a-binding protein 1, Protein phosphatase 2/4/6 regulatory subunit, and Renal carcinoma antigen NY-REN-16, plays a crucial role in immune response. It is associated with surface IgM-receptor and may be involved in signal transduction. Furthermore, it regulates the catalytic activity of phosphatases PP2A, PP4, and PP6, protecting their catalytic subunits from degradation.

Therapeutic significance:

This protein is linked to Intellectual developmental disorder, X-linked, syndromic 28, characterized by agenesis of the corpus callosum and severe intellectual deficit. Understanding the role of Immunoglobulin-binding protein 1 could open doors to potential therapeutic strategies for this disorder.